|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.965 USD | -1.17% |
|
-0.66% | +8.73% |
Business description: Perspective Therapeutics, Inc.
Number of employees: 165
Sales by Activity: Perspective Therapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Radiopharmaceutical development | - | - | 1.43M | 1.45M | 884K |
Isotope-Based Medical Devices | 10.05M | 10.8M | - | - | - |
Geographical breakdown of sales: Perspective Therapeutics, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 10.05M | 10.8M | 1.43M | 1.45M | 884K |
Non - United States | 5.03K | - | - | - | - |
Executive Committee: Perspective Therapeutics, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Johan Spoor
CEO | Chief Executive Officer | 54 | 2023-02-04 |
Joel D. Sendek
DFI | Director of Finance/CFO | 59 | 2025-09-03 |
Paul Lyne
CTO | Chief Tech/Sci/R&D Officer | - | 2026-07-07 |
David Hauser
CTO | Chief Tech/Sci/R&D Officer | - | 2022-03-31 |
Markus Puhlmann
CTO | Chief Tech/Sci/R&D Officer | 55 | 2023-02-02 |
Composition of the Board of Directors: Perspective Therapeutics, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Johan Spoor
BRD | Director/Board Member | 54 | 2023-02-04 |
Lori Woods
CHM | Chairman | 63 | 2023-02-02 |
| Director/Board Member | 60 | 2023-02-04 | |
Frank Morich
BRD | Director/Board Member | 71 | 2023-02-04 |
Heidi Henson
BRD | Director/Board Member | 60 | 2023-05-31 |
| Director/Board Member | 56 | 2025-09-02 |
Company details: Perspective Therapeutics, Inc.
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.17% | -0.66% | -19.62% | -38.60% | 342M | |
| +1.29% | +3.46% | +7.10% | +16.36% | 49.47B | |
| +0.21% | +12.90% | +493.60% | +590.98% | 43.97B | |
| +3.51% | +14.00% | +23.45% | +80.73% | 39.6B | |
| +1.47% | +3.32% | +33.88% | +8.71% | 39.29B | |
| +0.85% | +7.66% | +21.22% | +48.78% | 32.43B | |
| -1.46% | +4.30% | - | - | 16.84B | |
| +1.09% | +3.96% | +32.51% | +122.68% | 16.49B | |
| +0.34% | +3.40% | +5.70% | +18.79% | 14.01B | |
| +0.98% | +16.87% | +81.17% | +23.99% | 12.77B | |
| Average | +0.70% | +5.87% | +75.45% | +96.94% | 26.52B | |
| Weighted average by Cap. | +1.03% | +5.95% | +107.30% | +138.89% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CATX Stock
- Company Perspective Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
